MA26905A1 - Derives de phenylglycine. - Google Patents

Derives de phenylglycine.

Info

Publication number
MA26905A1
MA26905A1 MA26921A MA26921A MA26905A1 MA 26905 A1 MA26905 A1 MA 26905A1 MA 26921 A MA26921 A MA 26921A MA 26921 A MA26921 A MA 26921A MA 26905 A1 MA26905 A1 MA 26905A1
Authority
MA
Morocco
Prior art keywords
derivatives
phenylglycin
physiologically acceptable
carbamimidoyl
solvates
Prior art date
Application number
MA26921A
Other languages
English (en)
Inventor
Leo Alig
Zbinden Katrin Groebke
Kurt Hilpert
Holger Kuehne
Ulrike Obst
Hans Peter Wessel
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA26905A1 publication Critical patent/MA26905A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D317/34—Oxygen atoms
    • C07D317/36—Alkylene carbonates; Substituted alkylene carbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/12—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines
    • C07C259/18—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines having carbon atoms of hydroxamidine groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Furan Compounds (AREA)
MA26921A 2000-05-23 2002-11-22 Derives de phenylglycine. MA26905A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00110881 2000-05-23

Publications (1)

Publication Number Publication Date
MA26905A1 true MA26905A1 (fr) 2004-12-20

Family

ID=8168800

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26921A MA26905A1 (fr) 2000-05-23 2002-11-22 Derives de phenylglycine.

Country Status (23)

Country Link
US (1) US6548694B2 (fr)
EP (1) EP1289939A1 (fr)
JP (1) JP3842132B2 (fr)
KR (1) KR100569517B1 (fr)
CN (1) CN1305839C (fr)
AR (1) AR028596A1 (fr)
AU (2) AU8177401A (fr)
BR (1) BR0110998A (fr)
CA (1) CA2408602C (fr)
EC (1) ECSP024360A (fr)
HU (1) HUP0302073A2 (fr)
IL (1) IL152581A0 (fr)
MA (1) MA26905A1 (fr)
MX (1) MXPA02011466A (fr)
NO (1) NO20025590D0 (fr)
NZ (1) NZ522412A (fr)
PE (1) PE20011314A1 (fr)
PL (1) PL361355A1 (fr)
RU (1) RU2268257C2 (fr)
UY (1) UY26721A1 (fr)
WO (1) WO2001090051A1 (fr)
YU (1) YU83602A (fr)
ZA (1) ZA200208899B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200101744T2 (tr) * 1998-12-14 2001-12-21 F. Hoffmann-La Roche Ag Fenilglisin türevleri.
DE10300049A1 (de) * 2003-01-03 2004-07-15 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen, die Faktor VIIa inhibieren
US6642386B2 (en) 2002-02-06 2003-11-04 Hoffmann-La Roche Inc. N-(4-carbamimidoyl-phenyl)-glycine derivatives
GB0211931D0 (en) * 2002-05-23 2002-07-03 Univ Liverpool Methods & device utilizing adsorption of molecules at a surface or interface
TW200410921A (en) * 2002-11-25 2004-07-01 Hoffmann La Roche Mandelic acid derivatives
EP1594505A4 (fr) 2003-02-11 2008-08-13 Bristol Myers Squibb Co Derives de phenylglycine utiles en tant qu'inhibiteurs de serine protease
JP2006517589A (ja) 2003-02-11 2006-07-27 ブリストル−マイヤーズ　スクイブ　カンパニー セリンプロテアーゼ・インヒビターとして有用なベンゼンアセトアミド化合物
DE10306202A1 (de) 2003-02-13 2004-08-26 Grünenthal GmbH Arzneimittel enthaltend substituierte 2-Aryl-Aminoessigsäure-Verbindungen und/oder substituierte 2-Heteroaryl-Aminoessigsäure-Verbindungen
US7917130B1 (en) 2003-03-21 2011-03-29 Stratosaudio, Inc. Broadcast response method and system
US7776804B2 (en) * 2005-03-16 2010-08-17 The Lubrizol Corporation Viscosity improver compositions providing improved low temperature characteristics to lubricating oil
US7056932B2 (en) 2003-12-19 2006-06-06 Hoffman-La Roche Inc. Heterocyclyl substituted 1-alkoxy acetic acid amides
WO2006041119A1 (fr) * 2004-10-13 2006-04-20 Eisai R & D Management Co., Ltd. Dérivés d’hydrazide
WO2006045010A2 (fr) * 2004-10-20 2006-04-27 Resverlogix Corp. Stilbenes et chalcones utilises pour la prevention et le traitement de maladies cardio-vasculaires
PE20061117A1 (es) 2005-01-10 2006-10-13 Bristol Myers Squibb Co DERIVADOS DE FENILGLICINAMIDA COMO INHIBIDORES DEL FACTOR VIIa
ATE455103T1 (de) * 2005-06-24 2010-01-15 Bristol Myers Squibb Co Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
WO2007103996A1 (fr) * 2006-03-09 2007-09-13 Bristol-Myers Squibb Company Inhibiteurs du facteur viia de type 2-(aryloxy)acétamide pouvant être employés en tant qu'anticoagulants
JP5016592B2 (ja) * 2006-03-24 2012-09-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 トリアゾロン誘導体
US7855194B2 (en) 2006-03-27 2010-12-21 Hoffmann-La Roche Inc. Pyrimidine, quinazoline, pteridine and triazine derivatives
DK2118074T3 (en) 2007-02-01 2014-03-10 Resverlogix Corp Compounds for the prevention and treatment of cardiovascular diseases
EP1967522A1 (fr) * 2007-03-07 2008-09-10 Novo Nordisk A/S Nouveaux inhibiteurs de coagulation sanguine
JPWO2009038157A1 (ja) * 2007-09-21 2011-01-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 ２，３−ジヒドロ−イミノイソインドール誘導体
WO2009079417A1 (fr) 2007-12-14 2009-06-25 Stratosaudio, Inc. Systèmes et procédés de programmation de supports et d'événements interactifs
RU2520098C2 (ru) * 2008-06-26 2014-06-20 Ресверлоджикс Корп. Способы получения производных хиназолинона
JP5635535B2 (ja) 2009-01-08 2014-12-03 レスバーロジックス コーポレイション 心血管疾患の予防および治療のための化合物
CA2992231C (fr) 2009-03-18 2022-03-29 Resverlogix Corp. Derives de la phenyl-quinazolin-4(3h)-one et de la phenyl-pyrido[2,3-d]pyrimidin-4(3h)-one et leurs compositions utiles comme agents anti-inflammatoires
KR20190091564A (ko) 2009-04-22 2019-08-06 리스버로직스 코퍼레이션 신규한 소염제
CN102887836B (zh) * 2011-07-18 2014-03-26 西南大学 L-苯甘氨酸衍生物及其应用
CN103945848B (zh) 2011-11-01 2016-09-07 雷斯韦洛吉克斯公司 被取代的喹唑啉酮的口服即释制剂
GB201118876D0 (en) * 2011-11-01 2011-12-14 Astex Therapeutics Ltd Pharmaceutical compounds
WO2014080290A2 (fr) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Amines cycliques servant d'inhibiteurs de bromodomaines
WO2014080291A2 (fr) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Dérivés biaryle servant d'inhibiteurs de bromodomaines
CA2895905A1 (fr) 2012-12-21 2014-06-26 Zenith Epigenetics Corp. Nouveaux composes heterocycliques en tant qu'inhibiteurs de bromodomaine
KR102662814B1 (ko) 2015-03-13 2024-05-03 리스버로직스 코퍼레이션 보체 관련 질환을 치료하기 위한 조성물 및 치료 방법
CN111072562B (zh) * 2019-11-07 2021-12-07 中山大学 一种四氢异喹啉衍生物及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE243192T1 (de) 1997-12-04 2003-07-15 Hoffmann La Roche N-(4-carbamimido-phenyl)-glycinamidderivate
WO1999041231A1 (fr) * 1998-02-17 1999-08-19 Ono Pharmaceutical Co., Ltd. Derives amidino utilises comme ingredients actifs et medicaments les contenant
TR200101744T2 (tr) * 1998-12-14 2001-12-21 F. Hoffmann-La Roche Ag Fenilglisin türevleri.

Also Published As

Publication number Publication date
AU8177401A (en) 2001-12-03
AR028596A1 (es) 2003-05-14
CA2408602A1 (fr) 2001-11-29
IL152581A0 (en) 2003-05-29
KR100569517B1 (ko) 2006-04-07
MXPA02011466A (es) 2003-04-25
EP1289939A1 (fr) 2003-03-12
UY26721A1 (es) 2001-12-28
AU2001281774B2 (en) 2005-03-10
US6548694B2 (en) 2003-04-15
KR20030007678A (ko) 2003-01-23
NZ522412A (en) 2004-05-28
NO20025590L (no) 2002-11-21
JP3842132B2 (ja) 2006-11-08
HUP0302073A2 (hu) 2003-09-29
CA2408602C (fr) 2008-01-08
NO20025590D0 (no) 2002-11-21
WO2001090051A1 (fr) 2001-11-29
RU2268257C2 (ru) 2006-01-20
PE20011314A1 (es) 2002-01-04
ZA200208899B (en) 2004-02-19
YU83602A (sh) 2006-05-25
CN1305839C (zh) 2007-03-21
JP2003534311A (ja) 2003-11-18
BR0110998A (pt) 2003-04-08
ECSP024360A (es) 2003-03-31
CN1430599A (zh) 2003-07-16
PL361355A1 (en) 2004-10-04
US20020004608A1 (en) 2002-01-10

Similar Documents

Publication Publication Date Title
MA26905A1 (fr) Derives de phenylglycine.
PT1109812E (pt) Pirrolobenzodiazepinas
ATE302775T1 (de) Carbolinderivate
TR200101744T2 (tr) Fenilglisin türevleri.
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
DE59709414D1 (de) Oxyiminopregnancarbolactone
DE60216233D1 (en) Carbolinderivate
ATE374190T1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
DE60121461D1 (de) Kondensierte pyridoindolderivate
PL375255A1 (en) Prodrugs of proton pump inhibitors
HK1045990A1 (en) Novel derivatives and analogues of galanthamin.
DE60112960D1 (de) Kondensierte pyridoindolderivate
MXPA05009282A (es) Derivados de anilina sustituidos.
ATE259813T1 (de) Triazolopyrimidinderivate
PT1204659E (pt) Benzofuranos serotoninergicos
DK1204658T3 (da) Benzofurylpiperazin-serotoninagonister
MXPA03003971A (es) Derivados de indol como inhibidores de pde5.
SG171472A1 (en) Substituted aniline derivatives
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
DE60124245D1 (de) Uridinderivate als antibiotika
TR200200017T2 (tr) Benzofuran türevleri
IS8034A (is) Imídasó[4,5-B]kínólínafleiður og notkun þeirra sem NO-myndunarhemla
TR200100475T2 (tr) N-İkameli azabisikloheptan türevlerinin üretimleri ve kullanımları.
SG145573A1 (en) Intermediates useful in the synthesis of hiv-protease inhibitors and methods for preparing the same
CY1110529T1 (el) Παρασκευη ν-υποκατεστημενων 2,7-διαλκυλο-4-υδροξυ-5-αμινο-8-αρυλοοκτανοϋλαμιδιων